



Ning et al. Cardiovascular Diabetology 2012, 11:76
http://www.cardiab.com/content/11/1/76ORIGINAL INVESTIGATION Open AccessDevelopment of coronary heart disease and
ischemic stroke in relation to fasting and 2-hour
plasma glucose levels in the normal range
Feng Ning1*, Lei Zhang1,2,3,4, Jacqueline M Dekker5, Altan Onat6,7, Coen DA Stehouwer8, John S Yudkin9,
Tiina Laatikainen2, Jaakko Tuomilehto1,2,10,11, Kalevi Pyörälä12 and Qing Qiao1,2 on behalf of the DECODE Finnish
and Swedish Study InvestigatorsAbstract
Background: Individuals who had normoglycemia but whose 2-hour plasma glucose (2hPG) concentrations did
not return to the fasting plasma glucose (FPG) levels during an oral glucose tolerance test (OGTT) have been shown
to have increased cardiovascular mortality. This is further investigated regarding to the first events of coronary heart
disease (CHD) and ischemic stroke (IS).
Method: Data from 9 Finnish and Swedish cohorts comprising 3743 men and 3916 women aged 25 to 90 years
who had FPG< 6.1 mmol/l and 2hPG< 7.8 mmol/l and free of CVD at enrolment were analyzed. Hazard ratios
(HRs) for first CHD and IS events were estimated for the individuals with 2hPG> FPG (Group II) compared with
those having 2hPG ≤ FPG (Group I).
Results: A total of 466 (115) CHD and 235 (106) IS events occurred in men (women) during a median follow-up of
16.4 years. Individuals in Group II were older and had greater body mass index, blood pressure, 2hPG and fasting
insulin than those in Group I in both sexes. Multivariate adjusted HRs (95% confidence intervals) for incidence of
CHD, IS, and composite CVD events (CHD+ IS) in men were 1.13 (0.93-1.37), 1.40 (1.06-1.85) and 1.20 (1.01-1.42) in
the Group II as compared with those in the Group I. The corresponding HRs in women were 1.33 (0.83-2.13), 0.94
(0.59-1.51) and 1.11 (0.79-1.54), respectively.
Conclusion: Within normoglycemic range individuals whose 2hPG did not return to their FPG levels during an
OGTT had increased risk of CHD and IS.
Keywords: Normoglycemia, Coronary heart disease, Ischemic stroke, IncidenceBackground
The role of hyperglycemia on the mortality from coron-
ary heart disease (CHD) [1,2], stroke [3,4] and other car-
diovascular diseases (CVDs) [5-7] has been well
investigated. Two-hour plasma glucose (2hPG) is a bet-
ter predictor than fasting plasma glucose (FPG) for inci-
dence of CHD [8,9] and ischemic stroke (IS) [10] among
individuals with hyperglycemia, but little is known about
their impact within normoglycemic range. Previous stud-
ies have shown that insulin resistance and declined beta* Correspondence: feng.ning@helsinki.fi
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reproduction in any medium, provided the orcell function are already presented in subjects with ele-
vated normal FPG and/or 2hPG [11-13]. The upper nor-
mal level of the FPG [14,15] or 2hPG [16] has been
found to increase the risk of type 2 diabetes. Our previ-
ous finding based on the DECODE (Diabetes Epidemi-
ology: Collaborative analysis Of Diagnostic criteria in
Europe) study demonstrated that individuals with
normoglycemia, whose 2hPG did not return to the FPG
levels during a standard 75 g 2-h oral glucose tolerance
test (OGTT) had a higher risk for mortality from CVD
and all-cause than individuals whose 2hPG returned to
their FPG levels or below them [17]. However, the early
DECODE study could not show a causal relationship be-
cause individuals with CVD at baseline could not bed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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consequence of existing CVD rather than a cause. To
further clarify the causal relationship between elevated
normal 2hPG and the development of the CVD events,
the current study is carried out based on the Finnish
and the Swedish DECODE cohorts who have complete
information on the occurrence of both fatal and non-
fatal events.
Participants and methods
Data from 9 Finnish and Swedish cohorts comprising
3743 men and 3916 women aged 25 to 90 years who
participated in the DECODE study were collaboratively
analyzed. The maximum duration of follow-up ranged
from 12.4 to 36.8 years among different cohorts with a
median follow-up of 16.4 years. The study populations
and methods used to recruit participants in the DE-
CODE study had been described previously [18-21].
Briefly, the database was collected from researchers in
Europe who had performed epidemiological surveys for
diabetes using a standard 2-h OGTT. Individuals’ data
from participating study cohorts were sent to the De-
partment of Chronic Disease Prevention of the National
Institute for Health and Welfare in Helsinki, Finland for
data analyses. In the current study, only the cohorts with
the prospective data on fatal and non-fatal events with
all required covariates of body mass index (BMI), blood
pressure, total serum cholesterol and smoking status
were included. Each study had been approved by the
local ethics committees, and the ethics committee of
the National Institute for Health and Welfare approved
the collaborative data analysis.
BMI was calculated as weight in kilograms divided by
height in meters squared (kg/m2). An individual with a
prior history of hypertension or having a systolic blood
pressure (SBP) ≥ 140 mmHg and/or a diastolic blood
pressure (DBP)≥ 90 mmHg and/or receiving antihyper-
tensive treatment was defined as having hypertension
[22]. To reduce the bias derived from differences in
methodology between studies, cohorts-specific Z-score
(Z = [X-μ]/σ) was calculated for fasting insulin concen-
trations. Insulin resistance was estimated by the homeo-
stasis model assessment according to formula of
HOMA-IR = (fasting insulin* FPG)/22.5 [23]. The smok-
ing status was classified as current smoker, ex-smoker or
non-smoker.
Individuals with a prior history of diabetes or newly
diagnosed diabetes (FPG ≥ 7.0 mmol/l and/or 2hPG ≥
11.1 mmol/l), or pre-diabetes (FPG 6.1-6.9 mmol/l and/
or 2hPG 7.8-11.0 mmol/l) at baseline were excluded
from the current data analysis. The data analysis was
restricted to the normoglycemic individuals defined by a
FPG< 6.1 mmol/l and a 2hPG< 7.8 mmol/l according
to the World Health Organization and InternationalDiabetes Federation 2006 criteria [24]. The normogly-
cemic individuals were further classified into Group I if
the 2hPG after a 75 g oral glucose load was equal to or
less than the FPG (2hPG ≤ FPG), or group II if the
2hPG was greater than the FPG (2hPG> FPG).
Definition of CHD and IS events
First-ever CHD and stroke events occurred before the
31 December 2008 were ascertained through computer-
ized record linkage of the unique national identification
numbers of the survey participants to the national
Causes of Death Registry and the national Hospital Dis-
charge Registry in both Finnish [25,26] and Swedish [27]
studies. Individuals with a history of CHD, myocardial
infarction, or stroke diagnosed before the baseline exam-
ination were excluded from the current data analysis.
Incident CHD events were defined as fatal CHD or non-
fatal myocardial infarction; IS events were defined as
fatal or non-fatal IS. The International Classification of
Diseases (ICD), 9th Revision (10th Revision), were used
for the classification of either fatal or non-fatal events:
ICD codes 410 to 414 (I20 to I25) for fatal CHD; 410 to
411 (I21 to I22, I24) for non-fatal acute myocardial in-
farction; 433, 434, 436 (I63 to I64) for fatal and non-fatal
IS. A composite CVD event consists of first events of
both CHD and IS.
Statistical analysis
A general linear model was used to estimate the mean of
a continuous variable adjusting for age and cohort. The
Chi-square test was performed to assess the difference
in proportions between groups. Interaction between sex
and glucose groups was examined. The Schoenfeld-test
was employed to assess the proportional hazards as-
sumption, and the results showed the proportionality as-
sumption was not violated. Cox proportional hazards
analysis was employed to estimate hazard ratios (HRs)
for CHD, IS incidence and composite CVD events in the
Group II as compared with the Group I. In the multi-
variate Cox model, we adjusted for age, cohort, BMI,
FPG, total serum cholesterol, smoking status and hyper-
tension status. The difference between 2hPG and FPG as
a continuous variable (2hPG-FPG) was also fitted in a
separate multivariate model adjusting for the baseline
FPG to examine whether the relationship was linear. In
addition, to check whether the “return of the 2hPG to the
FPG level” was determined by the FPG levels, the com-
parison of Group II versus Group I was further assessed
by dividing the FPG into two strata of FPG ≤ 5.6 mmol/l
and FPG 5.6-6.1 mmol/l. The statistical analyses were
performed using SPSS version 18.0 software (SPSS Inc.
Chicago, USA) and STATA version 11.0 software (Stata
Corp., TX, USA). A p-value less than 0.05 (two sided
tests) was considered statistically significant.
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Baseline characteristics of the participants are presented
in Table 1. During a median follow-up of 16.4 years, a
total of 466 (115) CHD, 235 (106) IS and 638 (213) com-
posite CVD events in men (women) were recorded. The
incidence of IS, composite CVD events were higher in
the Group II than in the Group I in men (p< 0.05), but
not in women (Table 2). Both incidences of CHD (7.2
per 1000 person-years versus 1.8 per 1000 person-years)
and IS (3.7 per 1000 person-years versus 1.6 per 1000
person-years) were higher in men than in women
(p< 0.05 for all comparisons). In addition, mean values
of various CVD risk factors such as age, BMI, 2hPG,
blood pressure, fasting insulin and HOMA-IR were sig-
nificantly greater in individuals in the Group II than in
those in the Group I in both sexes (p< 0.05 for all com-
parisons), except for BMI and systolic blood pressure in
women.
Since the interaction between the two glucose groups
and sex was statistically significant (p< 0.001), data ana-
lyses were made separately for men and women.
Multivariate-adjusted HRs for IS and composite CVD
events were significantly higher in Group II than in
Group I in men, but not in women (Table 3). The sur-
vival profile was better in group I than in group II for
composite CVD events in both sexes (Figure 1). Re-
placing the hypertension status (yes versus no) with con-
tinuous systolic blood pressure in the Cox model did not
change the results substantially (data not shown). HRs
corresponding to a one unit increase in the difference
between 2hPG and FPG concentrations (2hPG-FPG)
were significantly increased for the CHD events in
women and composite CVD events in all individuals
(Table 3).Table 1 Baseline characteristics of study cohorts and number







East–West Study 125/- 76 (70–90) 5.2 (0.04)
FINRISK 1987 859/1006 53 (44–64) 5.1 (0.01)
FINRISK 1992 496/747 53 (44–64) 5.2 (0.01)
Helsinki Policemen Study 578/- 45 (31–69) 5.7 (0.02)
Oulu Study 93/172 55 (55–55) 5.4 (0.03)
Vantaa Study 120/168 65 (64–66) 5.2 (0.03)
Sweden
Malmö Prevention Project -/821 54 (48–57) 5.5 (0.02)
MONICA 923/1002 45 (25–74) 5.1 (0.01)
ULSAM 549/- 71 (70–73) 5.1 (0.02)
Total 3743/3916 53 (25–90) 5.2 (0.01)
*Age-adjusted means (standard error). FPG, fasting plasma glucose; 2hPG, two-hour
Monitoring of trends and determinants in cardiovascular disease; ULSAM, the UppsStratified data analysis was also performed by FPG of
≤ 5.6 mmol/l and 5.6-6.1 mmol/l, and by age of< 60 years
and ≥ 60 years for both men and women combined.
Multivariate-adjusted HRs (95% CIs) for the composite
CVD events for Group II as compared with Group I
were 1.09 (0.91-1.30) and 1.41 (1.06-1.86) in the lower
and the higher FPG categories; and 1.16 (0.96-1.40) and
1.27 (0.99-1.64), respectively, in the younger and older
age groups. In addition, the same data analysis was also
made in a subgroup of individuals who had fasting insu-
lin measurements (n = 4082), producing an HR (95% CI)
of 1.10 (0.90-1.34) in a model without fasting insulin, to
1.09 (0.89-1.33) when the model fitting with fasting insu-
lin, and to 1.10 (0.90-1.34) when replacing fasting insulin
with HOMA-IR. Neither the fasting insulin levels nor
the HOMA-IR changed the results substantially. The
HR (95% CI) for the composite CVD events was 1.07
(0.89-1.30) and 1.08 (0.89-1.30), respectively in models
without and with physical activity and education in a
subgroup of participants (n = 5331).
Discussion
In these prospective cohort studies, 11.0% of the partici-
pants who had normoglycemia at baseline developed first
CHD or IS events during a median follow-up of 16.4 years.
The risk to develop the CHD or IS was increased in
people whose 2hPG was higher than whose FPG.
Two-hour plasma glucose concentration is a better
predictor than FPG for the incidence of CHD [8,9] and
IS [10] among general populations with hyperglycemia.
Moreover, post-challenge glucose concentrations con-
tribute to a greater risk on the patients with CHD [28]
or IS [29-31] than slightly elevated FPG. In contrast,
FPG was better predictor than 2hPG for total mortalityof first events of CHD and IS
2hPG*
(mmol/l)
No. of events (men/women) Maximum (Median)
follow-up yearsCHD IS
5.4 (0.10) 27/- 24/- 16.8 (10.4)
5.5 (0.03) 142/59 57/46 21.0 (20.8)
5.5 (0.03) 32/18 8/11 16.0 (15.9)
5.3 (0.05) 141/- 77/- 36.8 (34.5)
6.1 (0.07) 4/4 5/5 17.3 (16.8)
6.2 (0.07) 16/15 14/9 17.9 (17.3)
6.7 (0.04) -/2 -/16 20.0 (14.6)
5.3 (0.03) 50/17 12/19 20.6 (16.4)
5.5 (0.06) 54/- 38/- 12.4 (10.2)
5.6 (0.01) 466/115 235/106 36.8 (16.4)
plasma glucose; CHD, coronary heart disease; IS, ischemic stroke; MONICA,
ala Longitudinal Study of Adult Men study.
Table 2 Characteristics of participants and incidence of CHD and IS according to FPG and 2hPG categories
Men Women
Group I Group II Group I Group II
2hPG≤ FPG 2hPG> FPG 2hPG≤ FPG 2hPG> FPG
no. (%) 1818 (48.6) 1925 (51.4) 1110 (28.3) 2806 (71.7)
Age (years) 50 (0.28) * 57 (0.27) 49 (0.25) * 53 (0.16)
Body mass index (kg/m2) 25.9 (0.08) * 26.3 (0.07) 25.6 (0.13) 25.9 (0.08)
FPG (mmol/l) 5.33 (0.01) * 5.18 (0.01) 5.23 (0.01) * 5.18 (0.01)
2hPG (mmol/l) 4.42 (0.02) * 6.23 (0.02) 4.55 (0.02) * 6.37 (0.01)
Fasting insulin (ρmol/l) −0.07 (0.03) *† 0.09 (0.03) −0.13 (0.04) * 0.04 (0.03)
HOMA-IR −0.04 (0.03)*† 0.10 (0.03) −0.13 (0.04)* 0.01 (0.03)
Total serum cholesterol (mmol/l) 6.11 (0.03) 6.06 (0.03) 6.07 (0.03) 6.08 (0.02)
Blood pressure (mmHg)
Systolic 138 (0.42) * 141 (0.41) 133 (0.59) 135 (0.37)
Diastolic 84 (0.25) * 86 (0.25) 82 (0.32) * 83 (0.20)
Current smoking (%) 32.9 * 23.3 24.8 * 18.9
Hypertension (%) 48.7 * 64.2 45.0 * 51.7
Incidence per1000 person-years (no.)
CHD 6.7 (225) 7.9 (241) 1.3 (24) 1.9 (91)
IS 2.8 (96) * 4.5 (139) 1.4 (25) 1.7 (81)
CHD+ IS 8.7 (293) * 11.3 (345) 2.6 (48) 3.5 (165)
Data are age- and cohort- adjusted means (standard error) or as noted. *p< 0.05 for difference between the two glucose groups in men or in women; †Z-score for
2443 men and 1639 women who had fasting insulin measurements. CHD, coronary heart disease; FPG, fasting plasma glucose; 2hPG, 2-hour plasma glucose;
HOMA-IR, homeostasis model assessment of insulin resistance; IS, ischemic stroke.
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study [32]. A number of studies have shown that IFG
and IGT reflect different pathophysiological mechanisms
of abnormal glucose homeostasis [33,34]. Fasting hyper-
glycemia is associated with reduced hepatic insulin re-
sistance and decreased first-phase insulin secretion,
while elevated post-challenge glucose concentration is
associated with peripheral insulin resistance and impair-
ment of both early- and late-phase insulin response
[35,36].Table 3 Hazard ratios and 95% confidence intervals for incide
CHD
HR 95% CI
Men (n = 3743)
Group II versus Group I 1.13 0.93-1.37
2hPG-FPG (continuous) 1.03 0.95-1.12
Women (n = 3916)
Group II versus Group I 1.33 0.83-2.12
2hPG-FPG (continuous) 1.24 1.03-1.50
Total (n = 7659)
Group II versus Group I 1.15 0.97-1.38
2hPG-FPG (continuous) 1.06 0.98-1.14
Adjusting for age, cohort, body mass index, FPG, total serum cholesterol, smoking s
coronary heart disease; 95% CI, 95% confidence interval; FPG, fasting plasma glucos
2hPG-FPG, the difference between 2hPG and FPG; HR, hazard ratio; IS, ischemic stroAmong individuals with normal glucose range, people
whose 2hPG did not return to their FPG levels during a
2-h OGTT had a significantly higher risk for future type
2 diabetes [16], worse cardiovascular risk profile [37]
and higher CVD mortality [17] compared with those
whose 2hPG were equal to or lower than their FPG
levels. This was further confirmed in our current study
with incident CVD events. The normoglycemic status is
a balance between glucose production and disposal
mediated through a synergistic effect of skeletal muscle,nce of coronary heart disease and ischemic stroke
IS CHD+ IS
HR 95% CI HR 95% CI
1.40 1.06-1.85 1.20 1.01-1.42
1.11 0.99-1.25 1.07 0.99-1.14
0.94 0.59-1.50 1.10 0.79-1.54
1.01 0.83-1.23 1.13 0.99-1.30
1.27 1.00-1.62 1.18 1.02-1.37
1.09 0.98-1.20 1.08 1.01-1.15
tatus and hypertension status, and sex when men and women combined. CHD,
e; Group I, 2hPG≤ FPG; Group II, 2hPG> FPG; 2hPG, 2-hour plasma glucose;
ke.
Figure 1 Survival curves for incidence of composite CVD events
derived from Cox regression analysis for Group I (solid line)
and Group II (dashed line) in men (A) and in women (B). The
analyses were adjusted for age, cohort, fasting plasma glucose, body
mass index, total cholesterol, smoking and hypertension status.
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levels have been shown to contribute to the progress to
diabetes and CVD among individuals with normogly-
cemia [16,37]. Our study showed that normoglycemic
individuals whose 2hPG did not return to FPG levels
had elevated fasting insulin levels and HOMA-IRcompared with those who did. Beta-cell dysfunction and
insulin resistance have been suggested to be present
already in individuals with normal glucose range [11,39].
Both insulin resistance and endothelial dysfunction have
been considered as the underlying mechanism contribut-
ing to the development of atherosclerosis [40-44]. Other
proposed factors include elevated plasma free fatty acids
concentrations, which appears to be an early trigger for
multiple pathways leading to atherogenesis in non-
diabetic healthy subjects [45], and elevated fetuin-A
levels which are associated with an increased risk of
myocardial infarction and IS in the general population
[46]. While these have been reported to be associated
with development of CVD in non-diabetic individuals,
to what extent these factors contribute to the increased
risk of CVD in people with high normal 2hPG is not
known, and needs to be further investigated.
The strengths of our study include a relatively long
duration of follow-up, a large sample size and a standard
2-h OGTT to define normoglycemia. In this collabora-
tive analysis, all studies were population-based with a
random sampling method except for the Helsinki Police-
men Study. To take into account the discrepancies be-
tween cohorts, the cohort was adjusted as a covariate in
the data analysis. The Finnish [25,26] and Swedish [27]
Causes of Death Register and Hospital Discharge Regis-
ter, the source of the data on CHD and IS events in this
study, have high coverage and diagnostic accuracy. Our
study has also certain limitations. The statistical power
of the analysis was relatively lower in women due to
small number of incident events. Other known cardio-
vascular risk factors, such as waist circumference,
HbA1c levels and dietary factors were not available for
all cohorts included in the current data analysis. Lipid-
lowering treatment, types of antihypertensive treatment
and hormone replacement therapy for the postmenopau-
sal women were not included in the current database.
Furthermore, we did not have any measurements of
markers of inflammation and endothelial dysfunction,
both of which have been shown to relate more strongly
to post-load than to fasting plasma glucose concentra-
tions, and might represent unmeasured confounders
which underlie the observed relationships [47,48]. To
what extent these missing variables will affect the results
is not known and need to be further investigated.Conclusion
In the normoglycemic range defined by both 2hPG and
FPG criteria, 2hPG after a 75 g OGTT unable to return
to the FPG level was associated with worse CVD profile,
elevated fasting insulin levels and increased CVD events.
The underlying mechanism and clinical implications
need to be further investigated.
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